Zacks Investment Research cut shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) from a buy rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Shares of H. Lundbeck A/S- (OTCMKTS HLUYY) opened at $51.24 on Wednesday. The stock has a market cap of $10,115.61, a PE ratio of 21.17, a PEG ratio of 0.93 and a beta of 0.17. H. Lundbeck A/S- has a 1 year low of $40.70 and a 1 year high of $66.67. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.13 and a current ratio of 1.36.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.watchlistnews.com/h-lundbeck-as-hluyy-downgraded-by-zacks-investment-research-to-hold/1806665.html.

H. Lundbeck A/S- Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.